Effects of Intratympanic Steroid on Cisplatin  Ototoxicity: An Electrophysiological and  Ultrastructural Study

Taş, Abdullah

doi:10.4999/uhod.181742

Cited by 3 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tinnitus is the most common and often the first symptom among these complaints ( 12 ). The route of administration, cumulative dose, age, dietary factors, serum protein levels, genetic factors, use of additional ototoxic drugs, presence of nephropathy, exposure to noise and history of cranial radiotherapy are among the factors that affect the incidence of ototoxicity ( 3 ).…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, it decreases antioxidant enzyme levels through the excessive production of free oxygen radicals. Along with the consumption of antioxidant enzymes, superoxide, hydrogen peroxide and toxic lipids result in the penetration of calcium into cochlear cells by triggering apoptosis ( 3 ). In case of the disruption of stability between the production of free oxygen radicals and the antioxidant defense mechanisms, oxidative stress may lead to cochlear cell damage or death ( 3 , 4 ).…”

Section: Discussionmentioning

confidence: 99%

“…Ototoxicity refers to the occurrence of the symptoms of hearing loss and/or balance disorder via functional impairment or cellular degeneration in the inner ear caused by exposure to different therapeutic agents and chemicals. There should be the development of sensorineural hearing loss of 20 dB or more in at least two subsequent frequencies so that it is possible to talk about ototoxicity in the audiological evaluation ( 1 , 2 , 3 ). Numerous drugs and chemicals such as antibiotics of the aminoglycoside group, many antineoplastic agents including cisplatin, some diuretics, anti-inflammatory and antimalarial drugs and some antiseptic solutions, arsenic, and ethyl and methyl alcohol are known to have ototoxic effects ( 1 , 2 ).…”

Section: Introductionmentioning

confidence: 99%

“…Cisplatin (cis-diamminedichloroplatinum-II) is a chemotherapeutic agent which is effectively, successfully, and commonly used to treat various malignant diseases such as testicular cancers, head and neck cancers, small cell lung cancer, ovarian cancers, central nervous system malignancies, gastric cancers, and bladder cancers ( 2 , 3 ). Cisplatin frequently causes ototoxicity and nephrotoxicity and may have significant adverse effects such as bone marrow suppression, gastrointestinal toxicity, and peripheral neuropathy that limit its use in clinical practice ( 1 , 3 ). In particular, nephrotoxicity and ototoxicity are major dose-limiting adverse effects.…”

Section: Introductionmentioning

confidence: 99%

“…These effects are dose-dependent, cumulative and usually lasting. Its nephrotoxic effects can be overcome with hydration; however, there is still no treatment to avoid its ototoxic effects ( 1 , 2 , 3 ).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Protective and Therapeutic Effect of Platelet-Rich Plasma on Experimental Cisplatin Ototoxicity

Gözaydın,

Ünal,

Özdemir

et al. 2023

TAO

View full text Add to dashboard Cite

Objective: Cisplatin is a chemotherapeutic agent with an ototoxic effect that is frequently used in head and neck cancers. There are studies in the literature conducted with various antioxidant substances to protect and/or prevent ototoxicity. This study aims to investigate whether platelet-rich plasma (PRP) has a protective and therapeutic effect on cisplatin ototoxicity. Methods: A total of 40 Sprague Dawley albino rats were divided into six groups as control group (n=6), PRP-only group (n=6), cisplatin group (n=6), cisplatin + PRP group (n=6), PRP + cisplatin group (n=6), and donor group (n=10). At the beginning of the study and the 8 th day, they were tested with distortion product otoacoustic emission (DPOAE). Assessment of DPOAE results was based on the signal-to-noise ratio in 2000, 3000, 4000, 6000, and 8000 Hz frequency bands. On the 8 th day, the rats were sacrificed. For histological examinations, the temporal bones were dissected and fixed. After hematoxylin and eosin staining, the tissues were evaluated by light microscopy. Results: In the DPOAE tests performed on the 0 th and 8 th days of the cisplatin group, it was observed that cisplatin caused hearing loss in the rat ears. It was determined that the cisplatin group at 2000 Hz, 3000 Hz and 4000 Hz had a significant decrease in hearing compared to all groups (p<0.015), while the cisplatin group at 6000 and 8000 Hz was characterized by hearing loss at a higher rate than all groups (p<0.001). At the end of the study, negative effects of cisplatin on both cellular dimensions (cytoplasmic vacuolization, cell degeneration, dilatation, apoptotic cells, nerve degeneration) and hearing function were observed. No protective or therapeutic effect of PRP on cisplatin ototoxicity was observed. Conclusion: Our study showed that platelet-rich plasma did not have a significant effect in the treatment of hearing loss due to cisplatin ototoxicity and in preventing hearing loss in rats.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Protective and Therapeutic Effect of Platelet-Rich Plasma on Experimental Cisplatin Ototoxicity

Gözaydın,

Ünal,

Özdemir

et al. 2023

TAO

View full text Add to dashboard Cite

show abstract

The Protective Effect of Platelet Rich Plasma Against Cisplatin-Induced Ototoxicity

Yurtsever

Baklacı

Güler

et al. 2020

Journal of Craniofacial Surgery

View full text Add to dashboard Cite

Cisplatin, a pharmacological agent widely used for treating many cancers, may cause serious side effects including ototoxicity, nephrotoxicity, and peripheral neuropathy. The present study aimed to investigate whether platelet-rich plasma (PRP) protects against cisplatin ototoxicity. Eight rats (16 ears) were divided into 2 groups: control group (4 rats, 8 ears) that received intratympanic saline and study group (4 rats, 8 ears) that received intratympanic PRP. Cisplatin (10 mg/day intraperitoneally) or vehicle was administered 2 times per day to the animals. Auditory brainstem responses were recorded preoperatively and postoperatively on day 4 and at week 3. The authors compared the morphological appearances of spiral ganglion cells and the organ of Corti and the density of spiral ganglion cells between treatment groups. The number of outer hair cells in the organ of Corti significantly decreased in the control group compared with that in the PRP group. Although no statistically significant difference was observed between the groups regarding ABR thresholds on day 4 (P = 0.083, a statistically significant difference was observed between groups at week 3 (P = 0.038). Our results suggest that PRP can prevent cisplatin-induced ototoxicity.

show abstract

The Effects of Memantine on Cisplatin-Induced Ototoxicity

Güven,

Erdoğan,

Arslan

et al. 2024

Audiol Neurotol

View full text Add to dashboard Cite

Introduction: We aimed to investigate electrophysiologically and histopathologically, the protective effects of intratympanic memantine, an N-methyl-D-aspartate receptor antagonist, on ototoxicity caused by cisplatin, an anti-neoplastic agent used in many types of cancer. Methods: Thirty-seven guinea pigs with a normal auditory function were randomly allocated to group 1 (Cisplatin; n=8), group 2 (Memantine; n=8), group 3 (Cisplatin+Memantine; n=8), group 4 (Cisplatin+Physiological Serum [PS]; n=8), and group 5 (Control; n=5). Auditory assessments were conducted using distortion product otoacoustic emissions (DPOAE) within a frequency range of 1-32 kHz, and auditory brainstem responses (ABR) within 8-32 kHz. A single dose of cisplatin (12 mg/kg) was administered intraperitoneally, followed by intratympanic administration of 0.2 mL of either memantine or PS to both ears at least half an hour before cisplatin administration. Subsequent auditory evaluations were conducted 72 h after cisplatin administration. Histopathological analyses were performed using light microscopy of the right ear and scanning electron microscopy (SEM) of the left ear. Results: Auditory evaluations conducted before and after treatment revealed significant findings. Specifically, within groups 3 and 4, ABR thresholds were elevated at all frequencies (p=0.00), whereas the DPOAE signal-to-noise ratios were reduced at frequencies of 8, 12, 16, and 24 kHz (p=0.001, p=0.01, p=0.01, and p=0.00, respectively). Histopathologically, both light microscopy and SEM revealed that the cisplatin+memantine group exhibited fewer hair cells and nuclear degeneration in the spiral ganglion than the cisplatin and cisplatin+PS groups. Additionally, the stria vascularis thickness was greater in the cisplatin+memantine group than in cisplatin and cisplatin+PS groups. Conclusion: Despite the negative electrophysiological findings, the histopathological outcomes suggest that intratympanic memantine may have a potential protective effect against cisplatin-induced ototoxicity. However, further investigations are warranted to corroborate these findings and elucidate the underlying mechanisms of action of memantine.

show abstract

Effects of Intratympanic Steroid on Cisplatin Ototoxicity: An Electrophysiological and Ultrastructural Study

Cited by 3 publications

References 26 publications

Protective and Therapeutic Effect of Platelet-Rich Plasma on Experimental Cisplatin Ototoxicity

Protective and Therapeutic Effect of Platelet-Rich Plasma on Experimental Cisplatin Ototoxicity

The Protective Effect of Platelet Rich Plasma Against Cisplatin-Induced Ototoxicity

The Effects of Memantine on Cisplatin-Induced Ototoxicity

Contact Info

Product

Resources

About